✅ Model Answer:
• Diagnosis: Microalbuminuria (early diabetic nephropathy).
• Evidence: ACR 30-300 mg/g (80 mg/g), type 1 diabetes for >5 years, HbA1c 8.5% (poor glycemic control), normal BP, normal eGFR.
• Next step: Start ACE inhibitor (or ARB) – renoprotective. Optimize glycemic control (target HbA1c <7%). Monitor ACR, BP, creatinine annually. Lifestyle modifications (diet, exercise). Consider SGLT2 inhibitors (if indicated).

✅ Model Answer:
• Definition: Diabetic nephropathy is a progressive kidney disease caused by long-standing diabetes mellitus.
• Pathophysiology:
- Hyperglycemia: Leads to non-enzymatic glycation of proteins (AGEs), activation of the polyol pathway, and oxidative stress.
- Intraglomerular hypertension: Hyperfiltration due to afferent arteriolar vasodilation (mediated by prostaglandins and nitric oxide).
- Glomerular basement membrane thickening and mesangial expansion (Kimmelstiel-Wilson nodules).
- Podocyte injury.
- RAS activation: Intrarenal renin-angiotensin system activation → efferent arteriolar vasoconstriction → further hyperfiltration.
• Stages:
- Stage 1: Hyperfiltration (GFR ↑).
- Stage 2: Silent period (normoalbuminuria).
- Stage 3: Microalbuminuria (ACR 30-300 mg/g).
- Stage 4: Macroalbuminuria (ACR >300 mg/g) + declining GFR.
- Stage 5: ESKD.

✅ Model Answer:
• Early (microalbuminuria):
- Asymptomatic.
- Normal BP (may develop later).
- Normal GFR.
- ACR 30-300 mg/g.
• Late (macroalbuminuria):
- Proteinuria (nephrotic-range possible).
- Edema (nephrotic syndrome).
- Hypertension.
- Declining GFR.
- Progressive CKD.
• Other: Usually no hematuria or RBC casts (unlike glomerulonephritis).
• Risk factors: Poor glycemic control, hypertension, duration of diabetes (>5 years for type 1; at diagnosis for type 2), family history, smoking.

✅ Model Answer:
• Annual screening (for type 1 diabetes >5 years):
- Urine ACR: On a spot urine sample (first morning preferred).
- Serum creatinine/eGFR.
- Blood pressure.
- HbA1c.
• If ACR is elevated:
- Repeat ACR on 2 of 3 samples within 3-6 months.
- Rule out other causes: Urinalysis (for RBCs/casts), renal ultrasound (to rule out obstruction), complement levels (if glomerulonephritis suspected).
• Renal biopsy: Not routinely performed unless atypical features (rapid decline in GFR, hematuria, nephrotic-range proteinuria without long-standing diabetes, or positive ANA).
• Ophthalmology: Screen for diabetic retinopathy (correlates with nephropathy).

✅ Model Answer:
• ACE inhibitor or ARB:
- First-line: Even if normotensive (renoprotective).
- Dose: Lisinopril 0.1-0.4 mg/kg/day or enalapril 0.1-0.5 mg/kg/day.
- Goal: Reduce ACR and slow GFR decline.
- Monitor: BP, potassium, creatinine.
• Glycemic control:
- HbA1c target: <7% (or <6.5% in some guidelines).
- Insulin therapy: Optimize regimen (MDI or insulin pump).
- New agents: SGLT2 inhibitors (dapagliflozin, empagliflozin) – reduce proteinuria and CKD progression.
• Blood pressure control: Target <130/80 mm Hg (or <120/75 in children).
• Lifestyle modifications: Low sodium diet, exercise, weight management, smoking cessation.
• Lipid management: Statins if LDL >100 mg/dL.
• Monitor: ACR, BP, creatinine, eGFR, HbA1c annually (or more frequently).

✅ Model Answer:
• Progressive CKD: Leading to ESKD (20-40% of patients with type 1 diabetes).
• Hypertension.
• Nephrotic syndrome: If proteinuria progresses to nephrotic range.
• Cardiovascular disease: Increased risk of MI, stroke, heart failure.
• Retinopathy: Microvascular disease correlates with nephropathy.
• Anemia of CKD.
• Bone disease: CKD-MBD.
• Infections: Increased risk due to immunosuppression (if nephrotic syndrome).
• ESKD: Requires dialysis or transplantation.

✅ Model Answer:
• Prognosis:
- Improved with early detection and treatment (ACE inhibitors, glycemic control).
- Microalbuminuria: Can regress with treatment (30-40% of patients).
- Macroalbuminuria: Higher risk of progression to ESKD.
- ESKD: 20-40% of type 1 diabetes patients develop ESKD by 20-30 years of diabetes.
- Renal transplantation: Successful; recurrence is rare.
• Long-term follow-up:
- Monitor ACR, BP, creatinine, eGFR.
- Monitor HbA1c.
- Monitor for complications.
- Multidisciplinary care: Endocrinology, nephrology, dietitian, ophthalmology.

✅ Model Answer:
• ACE inhibitors (lisinopril, enalapril): Block the renin-angiotensin-aldosterone system (RAAS).
• Mechanism of action:
- Reduce efferent arteriolar vasoconstriction → reduce intraglomerular pressure → decrease proteinuria.
- Reduce angiotensin II-mediated fibrosis and inflammation.
• Indications:
- Microalbuminuria (ACR 30-300 mg/g) – even if normotensive (ADA guidelines).
- Macroalbuminuria (ACR >300 mg/g).
- Hypertension.
• Dose: Start low, titrate up (e.g., lisinopril 0.1 mg/kg/day, max 0.4 mg/kg/day).
• Monitoring: BP, serum potassium, creatinine (risk of hyperkalemia, AKI).
• Benefits: Reduce proteinuria, slow GFR decline, reduce cardiovascular events.
• Contraindications: Pregnancy, bilateral renal artery stenosis.